表皮生长因子受体
西妥昔单抗
抗体依赖性细胞介导的细胞毒性
体内
表皮生长因子受体抑制剂
抗体
封锁
癌症研究
癌症
药理学
化学
结直肠癌
生长抑制
毒性
受体
细胞毒性
免疫学
细胞生长
激酶
中和抗体
医学
免疫疗法
碎片结晶区
体外
T细胞
癌细胞
对抗
细胞
生长因子受体
作用机理
信号转导
作者
Jia Liu,Jingbo Ma,Shuming Lin,Wei Dai,Jia Lu,Min Wu,Yifan Wang,Huilin Zheng,Shuaixiang Zhou,Yang Liu,Feifei Wang,Bin Li,Zhihai Wu,Wangwang Liu,Jing Lyu,Yayao Yan,Jinling Xu,Jian Guan,Liang-Yong Xia,Huisi Liu
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-09-01
卷期号:: OF1-OF18
标识
DOI:10.1158/0008-5472.can-25-5580
摘要
Potent and sustained inhibition of epidermal growth factor receptor (EGFR) signaling is critical for suppressing colorectal cancer (CRC) growth, yet current EGFR therapies are often limited by incomplete EGFR blockade and on-target/off-tumor toxicities, particularly skin rash. Here, we co-targeted EGFR and cadherin-17 (CDH17) with a bispecific antibody (bsAb), overcoming these limitations by reducing skin-related toxicities and achieving superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies. Mechanistically, the high-affinity CDH17-binding arm anchored the EGFR/CDH17 bsAb to the tumor cell surface, facilitating rapid engagement of unbound or newly synthesized EGFR. This "anchor and capture" mechanism allowed the EGFR/CDH17 bsAb to achieve superior and more sustained suppression of the EGFR pathway than cetuximab and amivantamab. Further incorporation of an anti-CD16A nanobody transformed the EGFR/CDH17 bsAb into a trispecific natural killer (NK)-cell engager. Extensive format screening revealed that NK cell activation is heavily influenced by the spatial distance between the tumor antigen-binding Fab and the anti-CD16A nanobody, with longer distances impairing the bulky CD45 phosphatase exclusion from the immunological synapse and leading to significantly reduced cytotoxicity. Consequently, the widely adopted Morrison-type antibody consistently underperformed compared to architectures with shorter CD16A-TAA-Fab spacing. The final optimized molecule was IBI3019, a CDH17/EGFR/CD16A trispecific antibody that integrates potent CDH17-enhanced EGFR blockade with optimal architecture for efficient NK cell engagement. It demonstrated superior in vivo efficacy and a good safety profile in cynomolgus monkeys, with no observable skin toxicity. These promising pre-clinical findings warrant the clinical development of IBI3019. .
科研通智能强力驱动
Strongly Powered by AbleSci AI